Oncology drugs

Two businessmen pushing giant puzzle pieces together as the sun sets behind them

TegMine bags tech from OBI to help fuel ADC ambitions

TegMine has landed certain rights to OBI's ADC tech, advancing the efforts of former Stemcentrx scientists to treat cancer by targeting carbohydrates.

Nick Paul Taylor Jun 6, 2025 10:00am

arrow back backwards u-turn turn around reverse

Ascletis slashes funds for former core programs in obesity pivot

Mar 26, 2025 10:00am

share price stock stock price shares falling falling

Pyxis' shares fall on lukewarm early ADC results in solid tumors

Nov 21, 2024 2:30pm

AstraZeneca pays $19M for Nona's preclinical cancer antibodies

May 23, 2024 5:58am

Takeda gets crafty with molecular glue deal worth $1.2B biobucks

May 23, 2024 5:30am

FDA's Richard Pazdur explains confirmatory trial rejection, more

Apr 8, 2024 6:00am